Postpartum Relapse Rates in Women with Relapsing Multiple Sclerosis and the Impact of Disease-modifying Drugs: A Systematic Review

被引：0
|
作者：
Hellwig, Kerstin [1 ]
Di Cantogno, Elisabetta Verdun [2 ]
Sabido, Meritxell [2 ]
机构：
[1] Ruhr Univ, St Joseph & St Elisabeth Hosp, Bochum, Germany
[2] Merck KGaA, Darmstadt, Germany
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1918
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Review: In relapsing-remitting multiple sclerosis, disease-modifying agents reduce annual relapse rates
    Weinshenker, Brian G.
    [J]. ANNALS OF INTERNAL MEDICINE, 2014, 160 (06)
  • [2] Disease-Modifying Drugs for Multiple Sclerosis in Pregnancy: A Systematic Review
    Lu, Ellen
    Wang, Bing Wei
    Guimond, Colleen
    Synnes, Anne
    Sadovnick, Dessa
    Tremlett, Helen
    [J]. NEUROLOGY, 2012, 78
  • [3] DISEASE-MODIFYING DRUGS FOR MULTIPLE SCLEROSIS IN PREGNANCY: A SYSTEMATIC REVIEW
    Charles, James A.
    [J]. NEUROLOGY, 2013, 80 (11) : 1068 - 1068
  • [4] Disease-modifying drugs for multiple sclerosis in pregnancy A systematic review
    Lu, Ellen
    Wang, Bing Wei
    Guimond, Colleen
    Synnes, Anne
    Sadovnick, Dessa
    Tremlett, Helen
    [J]. NEUROLOGY, 2012, 79 (11) : 1130 - 1135
  • [5] A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis
    Hellwig, Kerstin
    Verdun di Cantogno, Elisabetta
    Sabido, Meritxell
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [6] The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments
    Edward J. D. Webb
    David Meads
    Ieva Eskytė
    Helen L. Ford
    Hilary L. Bekker
    Jeremy Chataway
    George Pepper
    Joachim Marti
    Yasmina Okan
    Sue H. Pavitt
    Klaus Schmierer
    Ana Manzano
    [J]. The Patient - Patient-Centered Outcomes Research, 2020, 13 : 583 - 597
  • [7] The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments
    Webb, Edward J. D.
    Meads, David M.
    Eskyte, Ieva
    Ford, Helen L.
    Bekker, Hilary L.
    Chataway, Jeremy
    Pepper, George
    Marti, Joachim
    Okan, Yasmina
    Pavitt, Sue H.
    Schmierer, Klaus
    Manzano, Ana
    [J]. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2020, 13 (05): : 583 - 597
  • [8] When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
    Alkhawajah, Mona
    Oger, Joel
    [J]. MULTIPLE SCLEROSIS INTERNATIONAL, 2011, 2011
  • [9] Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis
    Amato, Maria Pia
    Fonderico, Mattia
    Portaccio, Emilio
    Pasto, Luisa
    Razzolini, Lorenzo
    Prestipino, Elio
    Bellinvia, Angelo
    Tudisco, Laura
    Fratangelo, Roberto
    Comi, Giancarlo
    Patti, Francesco
    De Luca, Giovanna
    Morra, Vincenzo Brescia
    Cocco, Eleonora
    Pozzilli, Carlo
    Sola, Patrizia
    Bergamaschi, Roberto
    Salemi, Giuseppe
    Inglese, Matilde
    Millefiorini, Enrico
    Galgani, Simonetta
    Zaffaroni, Mauro
    Ghezzi, Angelo
    Salvetti, Marco
    Lus, Giacomo
    Florio, Ciro
    Totaro, Rocco
    Granella, Franco
    Vianello, Marika
    Gatto, Maurizia
    Di Battista, Giancarlo
    Aguglia, Umberto
    Logullo, Francesco Ottavio
    Simone, Marta
    Lucisano, Giuseppe
    Iaffaldano, Pietro
    Trojano, Maria
    [J]. BRAIN, 2020, 143 : 3013 - 3024
  • [10] Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland
    Bailey, B.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2011, 180 (02) : 337 - 341
12345